Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry†
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- Keywords
- Mantle cell lymphoma, chemotherapy, maintenance, rituximab,
- MeSH
- Survival Analysis MeSH
- Cyclophosphamide MeSH
- Doxorubicin MeSH
- Combined Modality Therapy MeSH
- Humans MeSH
- Lymphoma, Mantle-Cell diagnosis drug therapy epidemiology mortality MeSH
- Follow-Up Studies MeSH
- Treatment Failure MeSH
- Prednisone MeSH
- Prognosis MeSH
- Proportional Hazards Models MeSH
- Antineoplastic Agents, Immunological administration & dosage adverse effects therapeutic use MeSH
- Antineoplastic Combined Chemotherapy Protocols MeSH
- Registries MeSH
- Rituximab administration & dosage adverse effects drug effects MeSH
- Maintenance Chemotherapy MeSH
- Vincristine MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Names of Substances
- Cyclophosphamide MeSH
- Doxorubicin MeSH
- Prednisone MeSH
- Antineoplastic Agents, Immunological MeSH
- R-CHOP protocol MeSH Browser
- Rituximab MeSH
- Vincristine MeSH
We analyzed 495 MCL patients from the Czech Lymphoma Study Group data registry. With the median follow-up of 4.4 years, 51.7% patients progressed or relapsed and 34.1% died. Five-year overall survival reached 65.3% and five-year progression free survival 44.1% of the patients. Maintenance rituximab (MR) after first line therapy improved overall and progression free survival compared to the patients under observation only (both p < .001). Elevated beta-2-microglobulin (p = .003), presence of systemic symptoms (p = .002), ECOG >0 (p = .003), age (p = .014), and MIPI (p < .001) were associated with MR failure. Patients who did not achieve complete remission have had two-fold higher risk of MR failure (p < .001). Autologous stem cell transplant reduced the risk of MR failure by 69% (p < .001). The MIPI and the beta-2-microglobulin were identified as independent predictors of MR failure (p = .02 and p = .03, respectively). Patients who relapsed/progressed on MR reached shorter OS calculated from the MR start compared to patients without failure (HR = 15.0; p < .001).
c Department of Hematology and Oncology University Hospital Brno Czech Republic
e Institute of Hematology and Blood Transfusion Prague Czech Republic
g Department of Pathology and Molecular Medicine University Hospital in Motol Prague Czech Republic
References provided by Crossref.org
Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
